tranexamic acid has been researched along with Cytokine Release Syndrome in 1 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benhamou, D | 1 |
| Keita, H | 1 |
| Ducloy-Bouthors, AS | 1 |
1 review available for tranexamic acid and Cytokine Release Syndrome
| Article | Year |
|---|---|
Coagulation changes and thromboembolic risk in COVID-19 obstetric patients.
Topics: Anticoagulants; Autoantibodies; Betacoronavirus; Blood Proteins; Cerebrovascular Disorders; Contrain | 2020 |